Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.

In conclusion, our study shows that efgartigimod has clear therapeutic potential in MuSK myasthenia gravis and forms an exciting candidate drug for many autoantibody-mediated neurological and other disorders.
PMID: 30851266 [PubMed - as supplied by publisher]

Source: Experimental Neurology - March 5, 2019 Category: Neurology Authors: Huijbers MG, Plomp JJ, van Es IE, Fillié-Grijpma YE, Majidi SK, Ulrichts P, de Haard H, Hofman E, van der Maarel SM, Verschuuren JJ Tags: Exp Neurol Source Type: research